**Abstract**

It is well documented that low dose racemic ketamine, a mixture of two enantiomers, has a rapid antidepressant effect within hours that may last for 1 to 2 weeks. Racemic ketamine probably will never become a major treatment of depression because it has significant schizophrenomimetic and drug abuse side effects. The mechanism of its rapid antidepressant actions continues to be a major target of current and future research. This presentation addresses the fact that the two enantiomers of racemic ketamine have overlapping but also different pharmacological actions that target either antidepressant, analgesic or anesthetic uses. Detailed pharmacological dose-effect studies for each enantiomer and their metabolites must involve classic basic science methodology. A wide range of ketamine concentrations vary from 50-10000 ng/ml (0.21 - 42.1 nmol/ml) in vitro and in vivo. After i.v administration, anesthetic concentrations are greater than 2,000 with peak levels as high as 10,000 ng/ml. Patients return to consciousness ∼1,100 ng/ml. Low dose ketamine has analgesic and antidepressant effects with venous plasma concentrations of ∼150 ng/ml i.v. and as low as 40 ng/ml oral administration. Given a preferential distribution of ketamine brain:plasma ratio of 6.5, its equivalent concentration is ∼227 ng/ml in brain. In vitro NMDAR antagonism has a Ki value of ∼190 ng/ml for S-(+)-ketamine and ∼360 ng/ml for R(-)-ketamine. These are similar to the low concentrations for antidepressant effects. In vivo, a low dose of racemic ketamine also inhibits serotonin reuptake. Compared to S-(+)-ketamine, the less potent anesthetic enantiomer R(-)-ketamine requires much more additional concentration effect studies for its analgesic and antidepressant effects.
